Lynkuet (Elinzanetant)
An FDA-approved daily pill for moderate-to-severe menopause hot flashes.
Hot Flash PillsA daily prescription pill (neurokinin receptor antagonist) that blocks NK3 receptors in the brain to reduce hot flashes and night sweats.
Last verified: · Updated:
Specific branded items that use this method. Compare manufacturer details, active ingredients, and regulatory status.
How well it works, what to watch for, who should avoid it, and the studies behind it.
Guideline status: Recommended
This method class covers NK3 antagonists and dual NK1/NK3 antagonists. In Phase 3 trials, fezolinetant 45 mg reduced moderate-to-severe hot flashes and night sweats by 2.53-2.55 episodes per day versus placebo at week 12 (between-group difference in least squares mean change, p<0.001), and elinzanetant 120 mg reduced them by about 3.2 episodes per day versus placebo at week 12 (between-group difference, p<0.001). Responder rates also differ between products, so no single percentage captures the class. NAMS 2023 lists fezolinetant as a Level I recommendation; the FDA approved elinzanetant in October 2025, after the 2023 statement was published, so the statement did not individually evaluate elinzanetant.
Monthly retail prices for neurokinin antagonist products are typically around $700-$780 for fezolinetant and about $740 for elinzanetant; with pharmacy discount coupons the cash price drops to roughly $485-$620 for fezolinetant and $615-$620 for elinzanetant. Actual cost depends on pharmacy, insurance, and manufacturer savings programs.
Blocks neurokinin-3 (NK3) and/or neurokinin-1 (NK1) receptors in the hypothalamus to interrupt the temperature-regulation pathway that triggers hot flashes and night sweats.
Hot Flash Pills requires blood tests (baseline and periodic liver function tests) to monitor safety during use.
Neurokinin receptor antagonists are a new class of non-hormonal prescription pills for menopause hot flashes and night sweats. They block neurokinin receptors in the hypothalamus, the part of the brain that regulates body temperature. By interrupting the pathway that triggers hot flashes, they reduce both the frequency and severity of vasomotor symptoms.
Two neurokinin receptor antagonists are FDA-approved. The FDA approved fezolinetant, an NK3 antagonist, in 2023, and approved elinzanetant, a dual NK1/NK3 antagonist, in 2025. In SKYLIGHT 1 and SKYLIGHT 2, fezolinetant 45 mg reduced daily hot flash and night sweat frequency by 2.53 to 2.55 episodes per day more than placebo at week 12 (p<0.001). In the OASIS 1 and 2 trials, elinzanetant 120 mg reduced daily frequency by about 3.2 episodes per day more than placebo at week 12. The Menopause Society (NAMS 2023) lists fezolinetant as a Level I recommendation; the FDA approved elinzanetant in October 2025, after the 2023 statement was published.
Fezolinetant carries an FDA boxed warning about the risk of hepatotoxicity (liver injury). Neurokinin antagonists can affect the liver, so you need baseline liver function blood tests before starting one. With NK3 antagonists such as fezolinetant, tests are repeated monthly for the first 3 months, then again at 6 and 9 months. With dual NK1/NK3 antagonists such as elinzanetant, a repeat test at 3 months is recommended. Do not take an NK3 antagonist if you have cirrhosis, severe kidney disease, or take CYP1A2 inhibitors such as fluvoxamine or ciprofloxacin. Dual NK1/NK3 antagonists are contraindicated in pregnancy and not recommended for people with moderate or severe hepatic impairment or end-stage renal disease. Avoid strong CYP3A4 inhibitors (including grapefruit juice) and strong or moderate CYP3A4 inducers; if you take a moderate CYP3A4 inhibitor, reduce the dose to 60 mg (one capsule). Elinzanetant can cause sleepiness and affect your ability to drive or do hazardous activities the next day, and people with a history of seizures should talk to their clinician before using it.
You need a prescription, which you can get through telehealth or a menopause specialist. You take it as a daily pill. Check our provider directory for clinics near you.
The research that backs Hot Flash Pills, with links to the public trial records.